An observational study in Pancreatic Diseases, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-04.
Sponsored by University Hospital, Toulouse · Observational
This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.
This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.
169 studies on the registry are indexed under Pancreatic Diseases; 62 are open to participants now.
This study's planned enrollment of 300 is close to the median of 330 across 81 observational studies indexed under Pancreatic Diseases.
Browse Pancreatic Diseases studies →University Hospital, Toulouse is the lead sponsor of 794 studies on the registry; 214 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with pancreatic disease
Exclusion Criteria:
Diagnostic tools
To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies
Time frame: 3 years after the first inclusion
New targets
To identify new screening targets
Time frame: 3 years after the first inclusion
Improvement of management
To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management
Time frame: 3 years after the first inclusion
Microbiota
Study of the microbiota of pancreatic diseases
Time frame: 3 years after the first inclusion
Clinical data access
To make available to the scientific community quality material with associated clinical data also of quality
Time frame: 3 years after the first inclusion
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse